Sales Boost Expected for Eli Lilly and Boehringer Ingelheim’s Type 2 Diabetes Drug, Jardiance, Following New Indication and Updated Guidelines

  • RSS Feed

December has brought welcoming news for Eli Lilly and Boehringer Ingelheim (BI), with the FDA approving a new indication for their type 2 diabetes (T2D) drug, Jardiance (empagliflozin), in reducing the risk of cardiovascular (CV) death in adults with T2D and established CV disease. Additionally, the American Diabetes Association (ADA) is in the process of publishing new 2017 Standards of Medical Care in Diabetes guidelines that will contain a new recommendation to consider the use of Jardiance in T2D patients at increased risk of CV death. Exact details regarding the new Jardiance recommendation within the guidelines is expected to be released before the end of the year. These events resulted from the positive outcomes from the EMPA-REG OUTCOME clinical trial, which investigated CV outcomes in more than 7,000 T2D patients who were at high risk for CV events.

Gain full access to this article

You must register to read the full Expert Insight article. Register for FREE today and access all our healthcare Expert Insights.


Registering for our Expert Insights is free and only takes a moment.

Following this you'll gain unlimited access to all of the latest, event-driven opinion put together by our teams of experienced analysts.

Send to a colleague


© GlobalData 2017. John Carpenter House, 7 Carmelite Street, London EC4 0BS.